01 — At a Glance
The Vaccine Maker With a Medical Degree But No Business License
- 52-Week High / Low₹582 / ₹305
- Q3 FY26 Revenue₹165 Cr
- Q3 FY26 PAT₹3.89 Cr
- Q3 EPS₹0.65
- TTM EPS-₹1.27
- Book Value / Share₹135
- Price to Book2.44x
- 3-Yr Sales Growth-5.44%
- 3-Yr ROE-6.22%
- Return (6-Month)-18.8%
The Real Story: Panacea Biotec is what happens when you give an excellent vaccine scientist a calculator and hope they’ll figure out profit margins on their own. They didn’t. Q3 FY26 PAT came in at ₹3.89 crore on ₹165 crore revenue — that’s a 2.36% net margin, which is less impressive than a street tea vendor’s profit. The stock is down 19.3% in 3 months. Their 3-year ROE is negative 6.22%. They haven’t paid a dividend since before most of their shareholders were born. Yet they hold ₹80+ crore in UNICEF orders and supply polio vaccines to 50+ countries. It’s like having a Ferrari engine but forgetting to install the fuel pump.
02 — Introduction
The Lab Coat Billionaires Who Can’t Read Excel Sheets
Panacea Biotec was founded in 1984. If you do the math, that’s 40 years of vaccine-making excellence paired with 40 years of financial incompetence. The company is acknowledged by the United Nations for supplying billions of polio vaccine doses to 50+ countries. They invented the world’s first fully-liquid pentavalent vaccine (EasyFive) and the world’s first fully-liquid hexavalent vaccine (EasySix). These are genuine innovations that changed global vaccination. Ask any epidemiologist — they’ll tell you Panacea Biotec’s vaccines saved millions of lives.
Now ask them if they’d buy the stock. Awkward silence.
The fundamentals read like a dark comedy. Revenue of ₹606 crore TTM, down from ₹661 crore a year ago. A negative PAT of ₹8 crore TTM. A cash balance that survives because of UNICEF advances, not organic operations. The 72.5% promoter holding (Dr. Rajesh Jain and family) hasn’t diluted the stock much, but it also hasn’t poured in capital to fix the mess. The company’s 3-year sales growth is minus 5.44%. Its 3-year profit growth is 21.4%, but only because you can’t grow much negative without bouncing into positive territory at some point — that’s not a feature, it’s just maths fighting back.
The December 2025 Update: ITAT quashed income tax assessments from 2005-06 to 2012-13, cancelling a ₹329.49 crore tax demand. That’s good news. In the same breath, the company received a fresh ₹10.23 crore tax demand for AY 2016-17 and a ₹45.71 crore demand for AY 2015-16. That’s bad news. Also, Hungary’s National Centre for Public Health and Pharmacy revoked GMP certificates for the Baddi facility in February 2026. That’s catastrophic news. But sure, let’s focus on the bright side.
03 — Business Model: Saving Lives, Destroying Shareholder Value
How To Make A Product That The Whole World Needs But Nobody Wants To Pay For
Panacea Biotec operates in four segments: Vaccines (50% of revenue), Pharma formulations (39%), nutraceuticals & food products, and other miscellaneous items. The vaccine business is the crown jewel — they’re one of India’s largest vaccine manufacturers, with a 50% market share in Tacrolimus (PanGraf) for transplant patients. They’ve supplied polio vaccines to GAVI, PAHO, UNICEF, and the Global Polio Eradication Initiative. When a global health emergency needs 1 billion vaccine doses, Panacea Biotec is on speed dial.
The problem: polio vaccine margins are thinner than a samosa sheet. International tenders are competitive as hell. Bulk orders mean bulk discounts. A UNICEF order that sounds like ₹100 crore in the press release often means ₹80 crore in actual revenue and ₹20 crore in profit if you’re lucky. The pharma formulation segment (pain, diabetes, cardiovascular, oncology) is supposed to be the margin machine, but it’s losing money. The nutraceuticals segment was supposed to be trendy, but nobody’s buying health powders from a company whose own P&L looks unhealthy.
Vaccines50%Revenue Mix
Pharma Formulns39%Revenue Mix
Promoter Hold72.5%Jain Family
Interest Coverage-7.60x🚨 Danger Zone
The UNICEF Story: In November 2025, UNICEF awarded Panacea Biotec a contract for Easyfive-TT worth ~US$4.75 million. In December, they increased it by US$8.93 million to ₹80 crore for CY2026-2027. That’s ₹140+ crore in future revenue from one customer. The company also has PAHO orders. On paper, the order book looks healthy. In reality, international vaccine margins are so thin that ₹140 crore in orders might deliver ₹35 crore in profit if the company executes flawlessly. Given their recent track record, optimism feels like a luxury they can’t afford.
04 — Financials Overview: The Heartbreak Hotel
Q3 FY26: Profit Margin So Low, Even The Tax Department Feels Sad
